Sign In
Buy CLRB
$2.57
+0.0400 (+1.58%)
At Close: Jul 31, 2026
Cellectar's blood cancer therapy succeeds in trial
06:41am, Monday, 08'th Jan 2024
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines
FLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
08:30am, Tuesday, 19'th Dec 2023
Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
08:30am, Tuesday, 05'th Dec 2023
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
02:19pm, Thursday, 02'nd Nov 2023
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
01:40pm, Thursday, 09'th Mar 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization
Cellectar to Participate at Upcoming Banking Conferences
09:05pm, Wednesday, 08'th Mar 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerci
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
01:30pm, Wednesday, 15'th Feb 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
01:30pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
01:30pm, Wednesday, 16'th Nov 2022 GlobeNewswire Inc.
Secures license to the patents at issue in the lawsuit Secures license to the patents at issue in the lawsuit
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
08:30pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
12:30pm, Friday, 21'st Oct 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
12:30pm, Thursday, 22'nd Sep 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization
Why Zoom Video Is Trading Lower By 11%; Here Are 28 Stocks Moving Premarket
11:36am, Tuesday, 23'rd Aug 2022 Benzinga
Gainers
Quotient Limited (NASDAQ: QTNT) shares rose 58.2% to $0.3070 in pre-market trading. Quotient recently reported a wider Q1 loss.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) shares rose 34.5% t
Cellectar Reports Financial Results for Second Quarter 2022
12:30pm, Friday, 05'th Aug 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization
